Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Lipocine Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
LPCN
Nasdaq
8731
https://www.lipocine.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Lipocine Inc
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
- Apr 11th, 2024 11:00 am
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
- Mar 28th, 2024 12:00 pm
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
- Mar 25th, 2024 12:00 pm
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
- Mar 7th, 2024 1:00 pm
Lipocine to Present at 36th Annual Roth Conference
- Mar 6th, 2024 1:00 pm
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
- Feb 6th, 2024 1:00 pm
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
- Feb 2nd, 2024 1:00 pm
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
- Jan 18th, 2024 1:00 pm
Lipocine to Present at Biotech Showcase 2024
- Dec 19th, 2023 1:00 pm
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
- Nov 13th, 2023 7:45 pm
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023
- Nov 8th, 2023 1:00 pm
Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023
- Nov 1st, 2023 12:00 pm
Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression
- Oct 26th, 2023 12:00 pm
Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference
- Oct 23rd, 2023 11:00 pm
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference
- Sep 19th, 2023 8:05 pm
LPCN: Trial Results Improve Outlook
- Aug 16th, 2023 10:02 am
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023
- Aug 10th, 2023 12:00 pm
LPCN: 1148 Shows Muscle Loss Reversal
- Jul 31st, 2023 10:13 am
LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis
- Jul 27th, 2023 10:30 am
Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference
- Jun 14th, 2023 12:00 pm
Scroll